Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psoriasis.

Mark Lebwohl1

  • 1Department of Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA. lebwohll@aol.com <lebwohll@aol.com>

Lancet (London, England)
|April 11, 2003
PubMed
Summary
This summary is machine-generated.

New biological therapies offer improved psoriasis treatment by targeting T cell activation and cytokine release. While initial safety data are promising compared to older drugs, long-term studies are needed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026
Same author

Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.

JAMA dermatology·2026
Same author

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Dermatology and therapy·2026
Same author

The Misdiagnosis of Pemphigus Foliaceus as Psoriasis.

International journal of dermatology·2026
Same author

Efficacy and Safety of Cosibelimab for Advanced Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel.

Journal of drugs in dermatology : JDD·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Area of Science:

  • Dermatology and Immunology
  • Molecular Biology of Skin Diseases

Background:

  • Psoriasis pathogenesis involves T lymphocyte activation, cytokine release, and keratinocyte proliferation.
  • Understanding disease mechanisms has driven therapeutic advancements.

Purpose of the Study:

  • To review recent breakthroughs in psoriasis treatment.
  • To discuss novel biological therapies targeting specific pathogenic pathways.
  • To evaluate current and emerging treatment options.

Main Methods:

  • Review of recent scientific literature on psoriasis pathogenesis and treatment.
  • Analysis of new biological therapies targeting key molecular pathways.
  • Comparison of efficacy and safety profiles of novel agents versus traditional therapies.

Related Experiment Videos

Main Results:

  • New biological therapies demonstrate variable degrees of clinical improvement in psoriasis.
  • Initial safety data suggest advantages over older systemic agents like methotrexate and ciclosporin.
  • Advancements in topical and phototherapy also expand treatment options.

Conclusions:

  • Recent therapeutic strategies have significantly improved psoriasis management.
  • Targeted biological treatments offer a promising new avenue for patients.
  • Further long-term safety and efficacy data are crucial for established use.